Renal safety parameters after switch to doravirine/islatravir (DOR/ISL 100/0.75 mg) once daily: week 48 results from 2 randomized, active-controlled Phase 3 trials, MK8591A-017 (P017) and MK8591A-018 (P018)

Conference Reports for NATAP

IAS 2023
July 23rd - 26th
12th IAS Conference on HIV Science


Renal safety parameters after switch to doravirine/islatravir (DOR/ISL 100/0.75 mg) once daily: week 48 results from 2 randomized, active-controlled Phase 3 trials, MK8591A-017 (P017) and MK8591A-018 (P018)

	IAS 2023 july 24